Press Releases

 
Press Releases
  Date Title and Summary View
May 5, 2016
CRANBURY, N.J., May 05, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Chip Baird, Chief Financial Officer, will present a corporate overview at the Bank of America Merrill Lynch 2016 Health Care Conference in Las Vegas, NV on Wed...
PDF
May 3, 2016
Positive CHMP Opinion for Broad Label of Migalastat for Fabry Disease in Patients with Amenable Mutations  Actively Enrolling Patients Across Multiple Sites in Clinical Study to Investigate Novel Enzyme Replacement Therapy for Pompe Disease Company to Remain Within Original Full-Year 2016 Net Cash Spend Guidance of $135M-$155M CRANBURY, N.J...
PDF
Apr 26, 2016
CRANBURY, N.J., April 26, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced a conference call and live audio webcast on Tuesday, May 3, 2016 at 8:30 a.m. ET to discuss financial results for the first quarter ended March 31, 2016. The call will be ...
PDF
Apr 1, 2016
Broad Label for All Fabry Patients with an Amenable Genetic Mutation Conference Call Today at 12:30 pm ET CRANBURY, N.J., April 01, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of rare and orphan diseases, today announced that the European Committee for Medicinal Products for Human Us...
PDF
Mar 22, 2016
CRANBURY, N.J., March 22, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, has initiated a reimbursed expanded access program (EAP) to provide Fabry patients who have amenable mutations with access to migalastat. The EAP will be implemented in certain t...
PDF
Mar 2, 2016
CRANBURY, N.J., March 02, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that Bradley L. Campbell, President and Chief Operating Officer, will present a corporate overview at the Cowen and Company 36th Annual Health Care Conference in ...
PDF
Mar 1, 2016
New Phase 3 Data for Migalastat for Fabry Disease Demonstrate Persistence of Positive Renal and Cardiac Effects and Substrate Reduction in Important Kidney Cell Type (Podocytes) Preclinical Proof-of-Concept Data Informed Ongoing Clinical Study of Novel Pompe Treatment Paradigm SAN DIEGO and CRANBURY, N.J., March 01, 2016 (GLOBE NEWSWIRE) --...
PDF
Feb 26, 2016
Committee for Medicinal Products for Human Use (CHMP) Opinion on Migalastat for Fabry Disease Likely in March  Clinical Study Underway to Investigate Novel Enzyme Replacement Therapy for Pompe Disease CRANBURY, N.J., Feb. 26, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies fo...
PDF
Feb 18, 2016
CRANBURY, N.J., Feb. 18, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, will host a conference call and live audio webcast on Friday, February 26, 2016 at 8:30 a.m. ET to discuss financial results for the year ended December 31, 2015. The call wi...
PDF
Feb 10, 2016
CRANBURY, N.J., Feb. 10, 2016 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a biotechnology company at the forefront of therapies for rare and orphan diseases, today announced that 3 oral presentations and 6 posters highlighting its development programs for Lysosomal Storage Disorders will be included at the 12th Annual WORLDSymposium...
PDF
Page:
1
... NextLast